Lucence Diagnostics

Swift Sensitive Surveillance. Because Cure Matters.

Proud to announce our new HemeMark service upgrade - now immediately available. HemeMark is a comprehensive NGS test supporting decisions in blood cancers.

Key features:
🔸 72 genes (from 45 genes) and microsatellite instability for more useful actionable information guiding treatment decisions.
🔸 0.05% VAF (from 0.1% VAF) for even greater sensitivity, powered by our proprietary mirror barcodes.
🔸 2 weeks turnaround time
🔸 run in our CAP-accredited and CLIA-licensed laboratory.

100% concordance of mutations in paired blood and bone marrow has been shown at >0.5% VAF threshold using HemeMark, and 86% at >0.1% threshold (Lim B et al, AACR 2023)

Product brochure : https://lnkd.in/g6i7_zY9

For non-US physicians only.

We are thrilled to announce a significant milestone for Lucence: our LiquidHALLMARK® assay has now received comprehensive Medicare coverage for patients with all types of advanced solid tumors.

This is a pivotal moment in making liquid biopsy accessible to a broader range of cancer patients across the United States.

https://www.lucence.com/lucencenews/lucence-confirms-comprehensive-medicare-coverage-for-liquidhallmark-and-demonstrates-sensitive-detection-of-lung-cancer-biomarkers-in-prospective-study/

We're honored to be a flagship company for the 20th anniversary of the US-Singapore Free Trade Agreement!

And so very glad our liquid biopsy technology can bridge better cancer care in both the USA and Singapore.

Join the first Genomics Tumor Board of 2024 on 30 January, Tuesday, 6-7.30pm at Mount Elizabeth Novena Hospital, Singapore.

Dr Gerry Kwok of the University of Hong Kong will also be speaking on liquid biopsies in cholangiocarcinoma, in a session chaired by Dr Choo Su Pin of Curie Oncology.

RSVP now at [email protected]. CME points accredited.

As we bid farewell to 2023, here are 7 moments we celebrated at Lucence:

✔ Medicare coverage achieved for LiquidHALLMARK®. We're grateful for the chance to contribute to cancer care for US cancer patients. Story link: https://lnkd.in/gVDMHJKb

✔ Evidence from the BRIGHTSTAR study with MD Anderson Cancer Center at ASCO23: combining ctRNA and ctDNA improves ALK fusion detection by 36%. Abstract link: https://lnkd.in/gbXA5qxi

✔ Evidence from LIQUIK, a prospective multicenter head-to-head study: 20% advantage shown by LiquidHALLMARK over an FDA-approved liquid biopsy test for detecting guideline-recommended biomarkers in lung cancer (Samol J et al. NACLC, Chicago, Dec 1-3, 2023)

Special mention to Drs Jens Samol, Richa Dawar, Jennifer Carney, James Orsini, Katherine Scilla, Gilberto Lopes, Tan Yew Oo, Chin Tan Min Chin, Toh Chee Keong and Goh Boon Cher.

✔ Granting of a PLA code on Oct 1, 2023 by the American Medical Association to facilitate payor and provider access to LiquidHALLMARK. Story link: https://lnkd.in/gm2zm7Es

✔ Launch of LucenceINSIGHT, our multicancer early detection (MCED) test, for earlier detection of 10 cancers. Story link: https://lnkd.in/gmQatsKn

Thanks to Deputy Prime Minister Heng Swee Keat and Enterprise Singapore for gracing and supporting the event!

✔Mirror barcode chemistry: Our new proprietary chemistry upgrade for our AmpliMARK platform has broken through a key barrier of 1 × 10−6 errors/base for even higher accuracy.

✔ 118% more patients served in 2023. At heart, we exist to provide life-changing information to help relieve pain, reduce suffering and extend life for more patients.

Our heartfelt thanks in 2023 to our partners and Lucence team members. None of this would have been possible without your dedication to patient care.

Excited for 2024! We'll keep making the world better together, united in our shared mission of better care!

Lucence unveiled the first real-world experience of LucenceINSIGHT™ for multi-cancer early detection at , together with scientific collaborators.

The study showed high (100%) specificity and positive predictive value (PPV), and good sensitivity (75%) in 264 asymptomatic subjects, consistent with earlier data.

All 3 subjects with positive blood signal were investigated and confirmed with colorectal cancer, kidney cancer and myeloproliferative neoplasm. 2 of these are not covered under conventional cancer screening guidelines. This highlights real-world performance of LucenceINSIGHT™ for earlier cancer detection.

Read the whole abstract here:
https://oncologypro.esmo.org/meeting-resources/esmo-asia-congress/initial-experience-in-a-real-world-asian-cohort-with-a-circulating-tumor-dna-ctdna-mutation-based-multi-cancer-early-detection-mced-assay

We were extremely honored to share our story with Singapore Prime Minister Lee Hsien Loong last week during his APEC 2023 visit to the Bay Area.

It has been a 6-year journey to securing US Medicare coverage for our liquid biopsy technology to help US patients.

We were glad to share a heartwarming case where a 50 year old lung cancer patient, mechanically ventilated in a Florida ICU, was treated with targeted therapy based on life-changing information from Lucence, and then subsequently went into remission.

Congratulations again to Enterprise Singapore on the opening of their new San Francisco Overseas Centre, helping Singapore-invented technology to overcome cancer globally!

Photo credits: Enterprise Singapore

So many important insights at our regular Genomic Tumor Board!

We learnt this month that 3 in 10 advanced prostate cancer patients in Singapore are eligible for targeted treatment. This from the first-ever Singapore-wide patient series shared by Dr Jens Samol of Tan Tock Seng Hospital.

Many thanks to Mount Elizabeth Novena Hospital, AstraZeneca Singapore and Singapore Society of Oncology for support!

Proud to share at RIE Day our journey in bringing liquid biopsy technology from Singapore to US Medicare national insurance coverage!

And even gladder to have the chance to thank the very important people who helped grow us, from A*STAR, Enterprise Singapore, Heliconia, SGInnovate and both public and private healthcare institutions!

We're excited to recommence our in-person Genomics Tumor Board on Tuesday evening!

7 complex patient cases from Singapore's public and private hospitals benefited from the combined expert recommendations from oncologists and other specialists spanning 6 of Singapore's public and private hospitals.

Special thanks to Mount Elizabeth Novena Hospital, Merck Singapore and Singapore Society of Oncology for support!

Looking forward to our November GTB!

Lucence Launches ctDNA and ctRNA Liquid Biopsy for Asia!

So glad to launch our combined ctDNA and ctRNA service to now benefit Asian cancer patients, following our Palo Alto launch in 2022!

The ctRNA panel identifies 36 actionable and emerging fusions that may be missed on a ctDNA panel alone, including MET exon 14 skipping, ALK, RET, ROS1, FGFR3, NTRK, and NRG1. 36% greater detection of fusions with additional ctRNA testing was shown in a collaboration with MD Anderson published at ASCO 23 (Heeke et al).

We also hosted a launch and seminar in conjunction with , bringing together partners and friends worldwide to discuss liquid biopsy from screening to therapy selection.

Following the first 2 generations of liquid biopsies of targeted PCR and ctDNA-only testing, Liquid Biopsy 3.0 is emerging, combining ctDNA and ctRNA for even more accurate therapy selection for cancer patients.

Many thanks to Drs Gilberto Lopes; Jason Chan; Steven Tucker; Jens Samol and Su-Pin Choo for their expert insights!

Key interim findings of LIQUIK, a prospective multicenter liquid biopsy study comparing Lucence’s LiquidHALLMARK with an FDA-approved liquid biopsy test and tissue NGS, will be presented at World Conference on Lung Cancer (WCLC) on September 9-13, 2023.

A second poster presentation will also present data on ctRNA amplicon-based sequencing providing an independent and potentially earlier measure of lung cancer detection to ctDNA.

Find out more about the results in our release here: https://www.lucence.com/lucencenews/interim-results-from-liquik-prospective-study-released-at-wclc-2023/

Lucence is featured in !

We’re so glad for the recognition of our team’s efforts to reduce cancer deaths worldwide with earlier detection combining circulating DNA and RNA testing.

10,000,000 people die every year from cancer - that’s 1 death every 3 seconds we hope to help prevent!

Check the full list here: www.forbes.com/100towatch

Lucence is pleased to partner with Innovent Biologics to improve access of Hong Kong patients with advanced bile duct cancer to FDA-approved targeted treatment.

This collaboration will improve access to accurate identification of FGFR2 fusions through an accurate and quick blood test – allowing more patients to benefit from effective targeted treatment.
https://www.lucence.com/lucencenews/lucence-and-innovent-announce-strategic-collaboration-on-bile-duct-cancer/

Lucence and Innovent Announce Strategic Collaboration on Bile Duct Cancer | Lucence Lucence and Innovent will partner to improve access of Hong Kong patients with advanced bile duct cancer to FDA-approved targeted treatment.

“The Dawn of Multi-Cancer Early Detection”

78% of cancer deaths in Asia are from unscreened cancers.

Multi-cancer early detection (MCED) blood testing can help earlier cancer detection, especially from unscreened cancers.

So glad to collaborate with Gleneagles Hospital Hong Kong for LucenceINSIGHT to be made available to help earlier cancer detection to save lives!

We're so pleased to engage with 癌症資訊網 cancerinformation.com.hk who have contributed so much to patient awareness and cancer survivorship!

The Chinese calligraphy 心 means heart, which is at the core of cancer care.

So important that liquid biopsies can inform better earlier detection for patients and families, for less deaths.

Clonal hematopoiesis is an emerging biomarker of cancer and longevity, even more strongly linked to heart disease compared to smoking and hypertension.

Learn more about how CH is detected and managed at the National Heart Centre Singapore-Lucence seminar on 22 July, Saturday, 1.30-3.30pm.

Our CEO Dr Min-Han Tan will be sharing more from the perspective of innovative genomic screening.

Register now: https://form.gov.sg/649ba6dc0fde85001338815d

We’re extremely honoured for our founder Min-Han Tan to be recognized in PM Lee Hsien Loong’s speech at Raffles Institution’s Bicentennial Founder’s Day 2023.

We will continue to strive for excellence in earlier cancer detection for patients in Singapore and worldwide!

Read the speech here: https://www.pmo.gov.sg/Newsroom/Speech-by-PM-Lee-Hsien-Loong-at-Raffles-Institution-Bicentennial-Founders-Day-2023

Speech by PM Lee Hsien Loong, delivered by Minister Chan Chun Sing, at Raffles Institution's Bicentennial Founder's Day 2023 Transcript of Speech by PM Lee Hsien Loong, delivered by Minister for Education Chan Chun Sing, at Raffles Institution's Bicentennial Founder's Day 2023 on 28 May 2023. You can watch the speech here: go.gov.sg/ri200-pmlee-speech

Read 5 of our co-authored abstracts here on multi-cancer early detection and ctDNA/ctRNA: https://bit.ly/lucence-asco2023

Our team is delighted to be at ASCO this year.

We would love to connect with you in person. Schedule a meeting with us (June 2-6) at https://calendly.com/maryjo-mullen/asco23

Lucence Showcases Liquid Biopsy Tech for Earlier Cancer Detection at 2023 ASCO Annual Meeting Lucence will be attending ASCO 2023 to present promising new data on earlier cancer detection based on its amplicon-based liquid biopsy technology.

Hot off the Press : Lucence liquid biopsies identified 4 times more ALK resistance mutations in blood, when compared to tissue NGS.

So much appreciation to Dr. Darren Lim and Dr. Stephanie Saw of the National Cancer Centre Singapore who described their experience with their caring for an ALK+ lung cancer patient over 8 years.

JTOCRR: https://www.jtocrr.org/article/S2666-3643(23)00051-6/fulltext

Diverse resistant mechanisms identified using serial next-generation sequencing in a patient with ALK-rearranged metastatic lung adenocarcinoma: Case report If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password

Reflecting on an exciting week when Singapore Deputy Prime Minister Heng Swee Keat launched LucenceINSIGHT™, kicking off a new era of earlier cancer detection when potentially curable!

With our sincerest thanks to Deputy Prime Minister Heng Swee Keat for gracing the launch of LucenceINSIGHT™ at our US headquarters.

Press Release: https://www.lucence.com/lucencenews/lucence-launches-lucenceinsight-to-detect-cancer-earlier/

Enterprise Singapore

Lucence Launches LucenceINSIGHT to Detect Cancer Earlier | Lucence Lucence unveiled LucenceINSIGHT™, its pioneering multi-cancer early detection (MCED) blood test, at their US headquarters. The event was attended by Singapore’s Deputy Prime Minister, Coordinating Minister for Economic Policies, and Chairman of the National Research Foundation, Singapore (NRF), ...

We're glad to announce our upgraded ctRNA panel*, with 36 new fusion partners being tested for. Powered by AmpliMark, our liquid biopsy now covers a total of 37 fusions.

We're proud to pioneer evidence to show that 43% more potentially actionable fusions can be detected on combined ctDNA and ctRNA liquid biopsy testing in NSCLC, as compared to ctDNA-only testing.

Now available in the United States.

*ctRNA is for investigational use

How can liquid biopsy detect cancer earlier, when it is most treatable?

Our CEO Dr. Min-Han Tan will speak on "Ending Cancer As We Know It in Southeast Asia" at the Head Foundation Dialogues in Singapore on April 18, 2023.

REGISTER HERE：https://us06web.zoom.us/webinar/register/6416794568366/WN_AzEJkUJiTJiGNTv5o07LwA #/registration

✨ 𝗗𝗜𝗔𝗟𝗢𝗚𝗨𝗘𝗦 | Cancer accounts for 10 million annual deaths worldwide, or 1 in 6 deaths. In Southeast Asia, 1.2 million people died of cancer in 2020 (WHO). In addition to the human toll, the estimated economic cost of cancer for Southeast Asia is $1.5 trillion over the next 30 years.

Early detection can play a big part in reducing cancer deaths. Liquid biopsies are blood tests that aim to detect cancer earlier for healthy individuals to cure early-stage disease and to identify the right drug treatments.

🗓️ Join us on 18 April 2023 at 6.30pm (GMT+8), to learn about the potential opportunities for liquid biopsies to contribute to better cancer care in Southeast Asia with a focus on multi-cancer early detection (MCED).

REGISTER NOW ➡️ https://us06web.zoom.us/webinar/register/6216794568422/WN_AzEJkUJiTJiGNTv5o07LwA

Lucence Min-Han Tan

"Lucence, which has headquarters in Singapore and the US, said 'This approval establishes Lucence as the first and only Asian-headquartered healthcare services company to secure United States national insurance coverage.'"

With this approval, we are proud to usher in this future of Singapore’s major entry into biomedical success, together with Enterprise Singapore.

So much gratitude to the Singapore public ecosystem for supporting our journey, including Agency for Science, Technology and Research (A*STAR), National University Cancer Institute, Singapore - NCIS, National Cancer Centre Singapore, Singapore General Hospital, Tan Tock Seng Hospital (TTSH) and Changi General Hospital (CGH).

Read Business Times article: https://bt.sg/5zb4
Read Straits Times article (paywalled): https://str.sg/iZT7

Singapore’s Lucence secures US Medicare approval for its cancer tests BIOTECH startup Lucence has secured approval for its Singapore-invented cancer tests from Medicare, a US government-funded healthcare insurance programme primarily for people aged 65 years and older. Read more at The Business Times.

We're so honored to contribute to the Hong Kong Precision Oncology Society roundtable on early cancer screening on February 26, 2023.

Cancer is a major challenge, with 10 million new patients annually in Asia, with the majority presenting in late stage.

Our CEO, Dr Min-Han Tan , spoke on the role of multi-cancer early detection (MCED) liquid biopsies to achieve earlier cancer detection, which could help reduce this burden for patients and their families.

So excited for liquid biopsies to change the future of healthcare!

Lucence is pleased to share that we have received Medicare coverage for our LiquidHALLMARK assay in lung cancer.

The decision covers all nine NCCN guideline-recommended molecular biomarkers in advanced lung cancer patients using LiquidHALLMARK.

Over 150,000 lung cancer patients over the age of 65 are diagnosed every year in the United States.

We are very grateful for this opportunity to contribute to the care of more patients!

Read more here: https://bit.ly/lucence-medicare

Lucence Announces Medicare Reimbursement Decision for LiquidHALLMARK® Assay in Lung Cancer | Lucence Lucence announced today that Palmetto GBA, a Medicare administrative contractor and leader in evaluating molecular diagnostic technology through its laboratory technology assessment group for the Molecular Diagnostics Services program (MolDX), has finalized a foundational Local Coverage Determinatio...

Lucence is glad to present at the 1st AACR Special Conference: Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) in Austin, Texas (Jan 23-25, 2023).

We report 100% variant concordance in 60 pairs of blood and bone marrow samples at 0.5% variant allele frequency from a patient cohort with myeloid malignancies. AmpliMark-based NGS testing with 0.1% detection limit was used.

These results support the use of AmpliMark-based liquid biopsy technology for non-invasive earlier blood-based AML and MDS detection and characterization.

Thanks to Dr Lim Zi Yi of the Centre for Clinical Haematology for driving this important research!

Abstracts here: https://lnkd.in/gNv2SgRn

Interested in how mirrorbarcodes and ctRNA can enable multi-cancer early detection?

We're committed to this mission and excited to share.

Our CEO Min-Han Tan and CFO Vee Kiet Chan are looking forward to chat at JPM2023!